KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Debt: 2020-2024

Historic Non-Current Debt for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $19.0 million.

  • Recursion Pharmaceuticals' Non-Current Debt fell 41.97% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 41.97%. This contributed to the annual value of $19.0 million for FY2024, which is 1627.70% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Non-Current Debt stood at $19.0 million for FY2024, which was up 1,627.70% from $1.1 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Non-Current Debt peaked at $19.0 million during FY2024, and registered a low of $536,000 during FY2022.
  • Over the past 3 years, Recursion Pharmaceuticals' median Non-Current Debt value was $1.1 million (recorded in 2023), while the average stood at $6.9 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first slumped by 94.45% in 2021, then skyrocketed by 1,627.70% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Non-Current Debt (Yearly) stood at $11.4 million in 2020, then plummeted by 94.45% to $633,000 in 2021, then declined by 15.32% to $536,000 in 2022, then spiked by 105.41% to $1.1 million in 2023, then skyrocketed by 1,627.70% to $19.0 million in 2024.